FDX1 and ovarian carcinoma: Developing small-molecule inhibitors of FDX1 could enhance copper accumulation in tumor cells, thereby promoting cuproptosis, particularly in malignancies that rely on mitochondrial respiration, such as certain ovarian cancers and clear cell renal cell carcinoma (ccRCC).